MedX Health Corp Initiates Key Commercial Validation Phase

MedX Health Corp has transitioned towards a teledermatology services model, focusing on its platform, DermSecure, for enhanced skin lesion assessments. Analyst Christian Orquera from First Berlin Equity Research has initiated coverage on MedX, recommending a "BUY" with a target price of CAD 0.28. The platform integrates MedX's SIAscopy technology, approved by the FDA, improving non-invasive lesion assessments.

MedX's current strategy involves commercial validation with Health Partners Group (HPG) in the UK. The multi-year agreement allows DermSecure's rollout in UK-based HPG client operations and indicates the scalability potential of the platform. MedX intends to expand to markets with delayed dermatology services, including Canada and the US. The outlook for 2026 anticipates noteworthy recurring revenue growth supported by regulatory and commercial validation of the technology.